Ginkgo Bioworks Holdings (DNA) Ratios
Ginkgo Bioworks Holdings Ratios
MX:DNA's free cash flow for Q2 2026 was $-46.89M. For the 2026 fiscal year, MX:DNA's free cash flow was decreased by $-2.62M and operating cash flow was $-44.27M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.92 | 5.62 | 6.11 | 8.38 | 12.79 |
| Quick Ratio | 4.92 | 5.62 | 6.11 | 8.36 | 12.76 |
| Cash Ratio | 1.74 | 5.24 | 5.76 | 7.61 | 11.50 |
| Solvency Ratio | -0.42 | -0.73 | -1.45 | -2.54 | -3.58 |
| Operating Cash Flow Ratio | -1.78 | -2.98 | -1.80 | -1.46 | -1.88 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -139.27M | $ -58.65M | $ 433.56M | $ 647.03M | $ 1.22B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.39 | 0.34 | 0.14 | 0.17 | 0.01 |
| Debt-to-Equity Ratio | 0.86 | 0.65 | 0.22 | 0.25 | 0.02 |
| Debt-to-Capital Ratio | 0.46 | 0.40 | 0.18 | 0.20 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.20 | 1.92 | 1.52 | 1.46 | 1.38 |
| Debt Service Coverage Ratio | 0.00 | -5148.03 | -8830.34 | -19288.98 | -760.72 |
| Interest Coverage Ratio | 0.00 | -5954.86 | -9294.69 | -20839.17 | -770.53 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 7.93 | 9.01 | 4.93 | 10.56 | 0.77 |
| Net Debt to EBITDA | -1.07 | 0.19 | 0.86 | 0.42 | 0.85 |
| Profitability Margins | |||||
| Gross Profit Margin | 81.48% | 83.02% | 78.52% | 57.25% | 58.68% |
| EBIT Margin | -184.30% | -241.11% | -355.07% | -444.06% | -584.94% |
| EBITDA Margin | -149.63% | -213.35% | -326.62% | -431.16% | -575.67% |
| Operating Profit Margin | -185.29% | -246.54% | -343.76% | -462.41% | -582.62% |
| Pretax Profit Margin | -184.30% | -241.15% | -355.11% | -444.08% | -585.69% |
| Net Profit Margin | -183.81% | -240.94% | -355.08% | -440.63% | -583.12% |
| Continuous Operations Profit Margin | -183.81% | -240.94% | -355.08% | -440.93% | -585.22% |
| Net Income Per EBT | 99.73% | 99.91% | 99.99% | 99.22% | 99.56% |
| EBT Per EBIT | 99.47% | 97.81% | 103.30% | 96.04% | 100.53% |
| Return on Assets (ROA) | -27.93% | -39.71% | -53.61% | -82.89% | -88.37% |
| Return on Equity (ROE) | -61.50% | -76.39% | -81.38% | -121.23% | -121.57% |
| Return on Capital Employed (ROCE) | -30.80% | -44.07% | -57.57% | -93.35% | -94.43% |
| Return on Invested Capital (ROIC) | -30.05% | -43.05% | -56.90% | -91.55% | -94.32% |
| Return on Tangible Assets | -29.43% | -41.92% | -58.23% | -88.89% | -90.24% |
| Earnings Yield | -67.87% | -107.34% | -27.22% | -74.26% | -16.71% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.08 | 10.12 | 14.05 | 5.69 | 2.09 |
| Payables Turnover | 2.98 | 2.72 | 5.79 | 19.54 | 15.84 |
| Inventory Turnover | 0.00 | 0.00 | 1174.02 | 46.80 | 38.58 |
| Fixed Asset Turnover | 0.32 | 0.38 | 0.64 | 0.66 | 2.15 |
| Asset Turnover | 0.15 | 0.16 | 0.15 | 0.19 | 0.15 |
| Working Capital Turnover Ratio | 0.39 | 0.34 | 0.24 | 0.33 | 0.32 |
| Cash Conversion Cycle | -70.81 | -98.08 | -36.72 | 53.32 | 160.75 |
| Days of Sales Outstanding | 51.54 | 36.08 | 25.98 | 64.20 | 174.34 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.31 | 7.80 | 9.46 |
| Days of Payables Outstanding | 122.35 | 134.16 | 63.01 | 18.68 | 23.05 |
| Operating Cycle | 51.54 | 36.08 | 26.29 | 72.00 | 183.80 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.08 | -6.16 | -6.09 | -6.01 | -7.70 |
| Free Cash Flow Per Share | -3.22 | -7.36 | -6.93 | -7.26 | -9.42 |
| Dividend Paid and CapEx Coverage Ratio | -22.32 | -5.11 | -7.24 | -4.82 | -4.49 |
| Capital Expenditure Coverage Ratio | -22.32 | -5.11 | -7.24 | -4.82 | -4.49 |
| Operating Cash Flow Coverage Ratio | -0.39 | -0.68 | -1.23 | -0.57 | -11.02 |
| Operating Cash Flow to Sales Ratio | -1.01 | -1.41 | -1.18 | -0.53 | -0.81 |
| Free Cash Flow Yield | -38.78% | -74.98% | -10.25% | -10.74% | -2.83% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.47 | -0.93 | -3.67 | -1.35 | -5.99 |
| Price-to-Sales (P/S) Ratio | 2.71 | 2.24 | 13.05 | 5.93 | 34.90 |
| Price-to-Book (P/B) Ratio | 0.91 | 0.71 | 2.99 | 1.63 | 7.28 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.58 | -1.33 | -9.75 | -9.31 | -35.30 |
| Price-to-Operating Cash Flow Ratio | -2.69 | -1.59 | -11.10 | -11.24 | -43.16 |
| Price-to-Earnings Growth (PEG) Ratio | 0.03 | 0.02 | 0.06 | 0.20 | -0.00 |
| Enterprise Value Multiple | -2.88 | -0.86 | -3.14 | -0.95 | -5.22 |
| Enterprise Value | 733.54M | 415.76M | 2.58B | 1.96B | 9.43B |
| EV to EBITDA | -2.88 | -0.86 | -3.14 | -0.95 | -5.22 |
| EV to Sales | 4.31 | 1.83 | 10.24 | 4.11 | 30.04 |
| EV to Free Cash Flow | -4.10 | -1.09 | -7.66 | -6.44 | -30.38 |
| EV to Operating Cash Flow | -4.29 | -1.30 | -8.72 | -7.78 | -37.14 |
| Tangible Book Value Per Share | 8.14 | 12.40 | 19.89 | 37.32 | 46.26 |
| Shareholders’ Equity Per Share | 9.17 | 13.80 | 22.61 | 41.41 | 45.68 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Revenue Per Share | 3.07 | 4.38 | 5.18 | 11.39 | 9.52 |
| Net Income Per Share | -5.64 | -10.54 | -18.40 | -50.20 | -55.53 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 0.99 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 1.43 | 1.87 | 2.31 | 2.20 | 3.66 |
| SG&A to Revenue | 1.08 | 1.08 | 1.53 | 2.99 | 2.75 |
| Stock-Based Compensation to Revenue | 0.48 | 0.49 | 0.91 | 4.04 | 5.12 |
| Income Quality | 0.55 | 0.58 | 0.33 | 0.12 | 0.14 |
Currency in USD
